PubMed Health⌕ Search

Biomedical subjects

M Yeadon

Publications and source records attributed to M Yeadon.

22 records · Page 2Linked to original sources

Comparative binding of mu and delta selective ligands in whole brain and pons/medulla homogenates from rat: affinity profiles of fentanyl derivatives.

The comparative binding characteristics of the mu opioid receptor selective ligand [3H]-[D-Ala2-MePhe4-glyol5]enkephalin [( 3H]-DAGO) and of the delta receptor ligand [3H]-[D-Pen2, D-Pen5]enkephalin[( 3H]-DPDPE) have been studied in homogenates of both whole brain and of pons/medulla regions from the rat. The receptor affinities of five 4-anilinopiperidine drugs (fentanyl derivatives) and of morphine have been determined by inhibition studies, using [3H]-DAGO and [3H]-DPDPE as markers of the mu and delta opioid binding sites, respectively. The concentration of delta opioid sites in pons/medulla was found to be approximately one third that of mu sites. The concentrations of both mu and delta sites in whole brain were similar to that of mu sites in pons/medulla. The rank order of affinities of the unlabelled drugs was dissimilar at the mu and delta sites. The most potent fentanyl derivatives exhibited negligible preference for the mu or delta sites, in contrast to the least potent compound, alfentanil which showed an extremely high mu-site selectivity.

Animals↗

A new method for determination of in vivo pA2 using infusions of naloxone to steady-state blood concentrations.

A method is described for the measurement of pA2 in vivo for the opioid antagonist naloxone, infused to predicted steady-state blood concentrations in rats. The method has been applied to antagonism of the respiratory depressant effects of opioid agonists. The basis of the technique rests upon determination of the plasma clearance of the antagonist whence appropriate loading doses and zero order infusion rate constants are calculated. The predicted concentrations of naloxone were verified by direct plasma measurement. Using the infusion protocol pA2 determinations by Schild analysis were significantly different from those obtained by bolus injection. The approach described provides more accurate estimates of in vivo pA2 and could be applied to other antagonists, species, and biological responses, overcoming many of the problems inherent in the use of bolus antagonist dosing, which is currently widely employed.

Alfentanil↗

Differences in the characteristics of opioid receptor binding in the rat and marmoset.

The density of mu and delta opioid binding sites in homogenates of rat and marmoset brain was determined using radiolabelled peptides with high receptor selectivity. In addition the affinity of mu and delta receptor binding of five drugs of the fentanyl series was measured. The ratio of mu: delta sites was similar within each species but the total receptor binding capacity in the rat was double that of the marmoset. The binding affinities for the delta site were dissimilar between the species and supports the hypothesis that the structure of this receptor shows phylogenetic differences. In contrast, mu site binding affinity was identical in rat and marmoset.

Animals↗

Binding characteristics of [D-Ala2-MePhe4-Glyol5] enkephalin and [D-Pen2,D-Pen5] enkephalin in rat brain: inhibition studies with fentanyl-like drugs.

We have investigated the binding characteristics of two tritiated enkephalin analogues [D-Ala2-MePhe4-Glyol5] enkephalin (DAGO) and [D-Pen2, D-Pen5] enkephalin (DPDPE) which are highly selective for mu and delta opioid sites respectively, in homogenates of whole rat brain and of the pons/medulla region. In addition, we have explored the binding profile of four 4-anilinopiperidine drugs (fentanyls) by means of inhibition studies. Our studies show that the delta involvement in pons/medulla of rat is small compared with that in whole brain and with mu binding in both whole brain and pons/medulla. In addition the rank order of affinities of the fentanyl series is the same at the mu and delta site, but the affinities are between 1 and 600-fold greater at the former site.

Animals↗